HomeCompareJDHCX vs ABBV

JDHCX vs ABBV: Dividend Comparison 2026

JDHCX yields 5.28% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $74.0K in total portfolio value
10 years
JDHCX
JDHCX
● Live price
5.28%
Share price
$7.33
Annual div
$0.39
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.3K
Annual income
$740.42
Full JDHCX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JDHCX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJDHCXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JDHCX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JDHCX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JDHCX
Annual income on $10K today (after 15% tax)
$449.04/yr
After 10yr DRIP, annual income (after tax)
$629.36/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,426.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JDHCX + ABBV for your $10,000?

JDHCX: 50%ABBV: 50%
100% ABBV50/50100% JDHCX
Portfolio after 10yr
$65.3K
Annual income
$12,756.09/yr
Blended yield
19.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JDHCX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JDHCX buys
0
ABBV buys
0
No recent congressional trades found for JDHCX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJDHCXABBV
Forward yield5.28%3.06%
Annual dividend / share$0.39$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$28.3K$102.3K
Annual income after 10y$740.42$24,771.77
Total dividends collected$6.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: JDHCX vs ABBV ($10,000, DRIP)

YearJDHCX PortfolioJDHCX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,228$528.28$11,550$430.00$322.00ABBV
2$12,569$554.36$13,472$627.96$903.00ABBV
3$14,028$579.94$15,906$926.08$1.9KABBV
4$15,615$604.95$19,071$1,382.55$3.5KABBV
5$17,338$629.33$23,302$2,095.81$6.0KABBV
6$19,204$653.04$29,150$3,237.93$9.9KABBV
7$21,225$676.03$37,536$5,121.41$16.3KABBV
8$23,409$698.27$50,079$8,338.38$26.7KABBV
9$25,767$719.73$69,753$14,065.80$44.0KABBV
10$28,311$740.42$102,337$24,771.77$74.0KABBV

JDHCX vs ABBV: Complete Analysis 2026

JDHCXStock

The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in high-yield/high-risk securities rated below investment grade. Securities rated below investment grade may include their unrated equivalents or other high-yielding securities the portfolio managers believe offer attractive risk/return characteristics.

Full JDHCX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JDHCX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JDHCX vs SCHDJDHCX vs JEPIJDHCX vs OJDHCX vs KOJDHCX vs MAINJDHCX vs JNJJDHCX vs MRKJDHCX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.